05/20/2026
Earlier this month, TriCan Health presented at the Pancreas Club meeting in Chicago. It was a great opportunity for pancreas surgeons and others in attendance to get access to a free platform to find best-match clinical trials for patients.
Many thanks to the Nikki Mitchell Foundation for the opportunity!
I had three key takeaways from the meeting:
1. RAS Inhibitors show incredible promise. The physicians in the audience were keenly focused on daraxonrasib and other drugs currently in trials (note - there are 42 (!) different trials in the US targeting RAS recruiting right now)
2. Personalization is king. Companies like Tempus AI provide genomic reports on the mutational burden within each tumor - so not just a binary measure of whether or not a biomarker is present, but to what extent. One pathologist presented research showing that two different tumors from a *single* origin site, metastasized in the *same* organ, might behave differently and therefore might benefit from individualized treatment. So not just personalized medicine per patient - personalized medicine *per tumor*. Amazing.
3. Organoids may help pinpoint effective therapies. An MD PhD at the meeting shared that cells taken from a tumor can be grown to ~1,000-cell organoids within about a week, and then those organoids can be used to select specific therapies, thereby avoiding resistance to typical standard of care adjuvant/neoadjuvant chemotherapies.
Incredible science continues to be conducted to address pancreatic cancer - many thanks to all the researchers and clinicians working every day to improve lives!
